| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780169 | Gynecologic Oncology | 2018 | 10 Pages |
Abstract
These results provide strong rationale for using BETi to extend therapeutic efficacy of PARPi to HR-proficient ovarian tumors and could benefit a substantial number of women diagnosed with this devastating disease.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Andrew J. Wilson, Matthew Stubbs, Phillip Liu, Bruce Ruggeri, Dineo Khabele,